Best Fit Profiles
- legacy NAD pathway support
Legacy NAD+ precursor
Nicotinamide
Nicotinamide can support NAD-related biochemistry, but clinical effects are context-dependent and may be less robust than newer precursors in some settings.
Evidence Level C
Evidence and Risk Labels
Evidence A/B/C reflects research maturity, and risk levels reflect monitoring needs. These labels support comparison, not diagnosis or treatment decisions.
See full scoring guideClinical Snapshot
- Effect Size
- Reliable pathway support with mixed functional outcomes
- Safety
- Moderate Risk
Dose-dependent tolerability issues.
Research Dosing
This reflects common ranges and protocols used in published studies, not personal medical advice.
- Typical Daily Dose
- 250-1000 mg
- Timing
- With meals
- Protocol Duration in Studies
- Variable; often 4-12 weeks in intervention studies
Upper-end doses may increase side-effect risk and should be individualized.
Related Conditions
- nad pathway
- metabolic support